COVID-19 Vaccines and Herd Immunity
COVID-19 Vaccines and Herd Immunity
With coronavirus vaccines now available, what are the timeline and prospects for "herd immunity" and return to a new normal? Marc Lipsitch of @HarvardPublicHealth returns to JAMA's Q&A series with Paul Biddinger, MD, Director of @MassGeneralHospital's Center for Disaster Medicine, to discuss. Recorded December 17, 2020.Additional Resources:
1. Article: Herd Immunity and Implications for SARS-CoV-2 Control
https://jamanetwork.com/journals/jama/fullarticle/2772167
2. Patient Information: What is Herd Immunity?
https://jamanetwork.com/journals/jama/fullarticle/2772168
3. Video livestream: Herd Immunity as a Pandemic Strategy
https://jamanetwork.com/learning/video-player/18558826
• Earn Free CME credits by watching JAMA Livestreams and completing a brief questionnaire.
• Claim 0.5 credits for each video at https://ja.ma/covidqa
• Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt
• To watch all the #JAMALive Q&A's Visit: https://ja.ma/covidqaytpl
• Don't forget to hit subscribe or click https://ja.ma/subscribe
Topics discussed in this interview:
0:00 Introduction
0:44 Dr Biddinger's role in Massachusetts
1:33 Vaccine distribution in Massachusetts
3:57 Who was prioritized for the vaccine?
4:38 Deciding who to prioritize
5:19 Distribution to hospitals
6:34 Are spouses also eligible for vaccination?
7:21 Are any doses going to nursing homes?
8:08 Initial rollout surprises
9:10 NAM vs ACIP rollout recommendations
11:55 Phase 2 distribution in Massachusetts
12:23 How long will the first phase take?
13:49 When does phase 2 begin?
14:29 Vaccinating influencers to address hesitancy
18:02 When do we get to herd immunity?
25:43 As more vaccines become available, who gets vaccinated next?
28:50 Number of people who need to be vaccinated
33:28 Moderna and Pfizer distribution in the coming weeks
34:37 Cold chain for Moderna
36:04 Vaccinating placebo recipients
39:40 Delaying second doses to vaccinate more people
42:04 Other vaccine candidates - what's next?
44:00 Distribution to low income countries
44:33 Vaccinating people previously infected with COVID
45:53 Path to mRNA vaccines being approved
48:26 Outlook for the next 2-3 months
52:39 Closing remarks
---------------------------------------------------------------------------------
For more from JAMA
• https://www.jama.com
• https://www.facebook.com/JAMAJournal
• https://www.twitter.com/JAMA_Current
• https://www.linkedin.com/company/jamanetwor
Follow the JAMA Network
• https://www.jamanetwork.com
• https://www.jamanetworkaudio.com
• https://www.facebook.com/JAMANetwork
• https://www.twitter.com/JAMANetwork
• https://www.instagram.com/JAMANetwork
• https://www.pinterest.com/JAMANetwork
=====================================================================
#JAMALive #Coronavirus #COVID19 #SARSCoV2 #Pandemic
Access Non-GMO, antigen-free, FDA-approved antiviral medication formulas used in Moderna's Spikevax.
VirusTC is a retail provider of concentrated FDA-approved antiviral medication formulas. VirusTC wholesale formulas are used in Moderna products. We sell FDA-approved formulas that are compatible with university medical plans, federal insurance coverage, and many major insurance providers. Our medications are part of tailored non-invasive cancer treatment plans available at a hospital in your region. VirusTC targets problems and provides care for the symptoms. Our products and services are used by Fred Hutch Cancer Center, John Hopkins, University Hospitals, the United States Military, and professional sports. During Operation Cancer Moonshot 2023, VirusTC products killed cancer cells, increased strength, and redeveloped muscles, tissue, and brain cells after cancer treatments.